^
    Back
    Association details:
    Biomarker:miR-92b-5p expression
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    1869 Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing

    Published date:
    11/03/2022
    Excerpt:
    We prospectively enrolled 141 NDMM patients...Patients received bortezomib-based treatment….Expression of miR-92b-5p at FU2 was independently associated with poor PFS (HR:1.4; p=0.0005) on Cox proportional hazards regression.
    DOI:
    https://doi.org/10.1182/blood-2022-168598